[go: up one dir, main page]

DE69940964D1 - Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums - Google Patents

Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums

Info

Publication number
DE69940964D1
DE69940964D1 DE69940964T DE69940964T DE69940964D1 DE 69940964 D1 DE69940964 D1 DE 69940964D1 DE 69940964 T DE69940964 T DE 69940964T DE 69940964 T DE69940964 T DE 69940964T DE 69940964 D1 DE69940964 D1 DE 69940964D1
Authority
DE
Germany
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940964T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Scot A Marsters
Mary A Napier
Robert M Pitti
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69940964D1 publication Critical patent/DE69940964D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69940964T 1998-12-22 1999-12-02 Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums Expired - Lifetime DE69940964D1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US13023299P 1999-04-21 1999-04-21
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
DE69940964D1 true DE69940964D1 (de) 2009-07-16

Family

ID=27557838

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69940964T Expired - Lifetime DE69940964D1 (de) 1998-12-22 1999-12-02 Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
DE69935085T Expired - Lifetime DE69935085T2 (de) 1998-12-22 1999-12-02 Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69935085T Expired - Lifetime DE69935085T2 (de) 1998-12-22 1999-12-02 Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums

Country Status (13)

Country Link
EP (1) EP1141284A2 (de)
JP (5) JP3993746B2 (de)
KR (1) KR100499600B1 (de)
AT (2) ATE432987T1 (de)
AU (1) AU768230B2 (de)
CA (1) CA2353799A1 (de)
DE (2) DE69940964D1 (de)
DK (1) DK1484338T3 (de)
ES (2) ES2327785T3 (de)
IL (3) IL143031A0 (de)
MX (1) MXPA01006330A (de)
PT (1) PT1484338E (de)
WO (1) WO2000037638A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053757A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
JP2002504308A (ja) 1997-11-22 2002-02-12 ハイセック インコーポレイテッド 胎児肝−脾臓のｃＤＮＡライブラリーから得られた新規ＥＧＦモチーフタンパク質
NZ528700A (en) * 1998-04-08 2005-02-25 Genentech Inc Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
HK1038755A1 (zh) 1999-01-15 2002-03-28 Biogen, Inc. Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
EP1198568B1 (de) * 1999-07-20 2007-07-25 Genentech, Inc. Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
MXPA02005758A (es) * 1999-12-09 2002-09-18 Sankyo Co Metodo para evaluar un remedio o agente preventivo para hiperlipidemia.
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HK1051543A1 (zh) * 2000-01-12 2003-08-08 Yale University Nogo受体介导的轴突生长封锁
NZ522741A (en) 2000-05-08 2005-06-24 Biogen Idec Inc Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2424834A1 (en) 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1904091A4 (de) 2005-07-07 2009-12-23 Univ Yale Zusammensetzungen und verfahren zur unterdrückung der axonalen wachstumshemmung
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2010226B1 (de) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP3141560A3 (de) 2008-05-06 2017-05-24 Genentech, Inc. Affinitätsgereifte crig-varianten
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Also Published As

Publication number Publication date
ATE353339T1 (de) 2007-02-15
IL143031A0 (en) 2002-04-21
JP2003529317A (ja) 2003-10-07
ES2281704T3 (es) 2007-10-01
KR100499600B1 (ko) 2005-07-07
IL186153A0 (en) 2008-01-20
ES2327785T3 (es) 2009-11-03
JP4037876B2 (ja) 2008-01-23
ATE432987T1 (de) 2009-06-15
JP2005237383A (ja) 2005-09-08
DE69935085T2 (de) 2007-08-23
AU1749900A (en) 2000-07-12
KR20010084882A (ko) 2001-09-06
IL186154A0 (en) 2008-01-20
PT1484338E (pt) 2007-05-31
JP2007222180A (ja) 2007-09-06
DK1484338T3 (da) 2007-06-11
EP1141284A2 (de) 2001-10-10
CA2353799A1 (en) 2000-06-29
DE69935085D1 (de) 2007-03-22
JP3993746B2 (ja) 2007-10-17
WO2000037638A3 (en) 2000-11-09
WO2000037638A2 (en) 2000-06-29
MXPA01006330A (es) 2002-07-02
AU768230B2 (en) 2003-12-04
JP2005245451A (ja) 2005-09-15
JP2007291116A (ja) 2007-11-08

Similar Documents

Publication Publication Date Title
ATE432987T1 (de) Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
DE60228997D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
WO2002026822A3 (en) Pumpcn compositions and uses thereof
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
ATE440109T1 (de) Methoden zur diagnose von tumoren
DE69940681D1 (de) Zusammensetzung und Verfahren zur Diagnose von Tumoren
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP2075335A3 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
EP1870464A8 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
KR100515858B1 (en) PRO617 Polypeptides
WO2000007545A3 (en) Apoptosis proteins
KR100515857B1 (en) PRO792 Polypeptides
KR100515856B1 (en) PRO618 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder
DE69939339D1 (de) Menschliches Synaptogyrin-ähnliches Protein und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition